Editorial: Mesenchymal stromal cells as treatment for chronic GVHD

Bone Marrow Transplantation

Volumn 46, Issue 2, 2011, Pages 163-164

  Ringden, O ^a   Keating, A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FATE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; DNA MODIFICATION; EDITORIAL; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC DISEASE; GRAFT VERSUS HOST REACTION; NOTE; SALVAGE THERAPY;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; SALVAGE THERAPY;

EID: 79951603654     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.275     Document Type: Editorial

References (18)

1. Ringden O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S (eds). Graft vs Host Disease, 2nd edn. Marcel Dekker, Inc.: New York, 1996, pp 525-559.
2. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276. (Pubitemid 11174888)
3. Weisdorf DJ. Chronic graft-versus-host disease: where is promise for the future? Leukemia 2005; 19: 1532-1535. (Pubitemid 43090395)
4. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667-2674.
5. Socie G, Devergie A, Cosset JM, Pierga JY, Esperou H, Girinski T et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49: 657-658. (Pubitemid 20110496)
6. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266. (Pubitemid 43273710)
7. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al. Treatment of severe acute graftversus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441. (Pubitemid 38586721)
8. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397. (Pubitemid 43847148)
9. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
10. Parekkadan B, Tilles AW, Yarmush ML. Bone marrowderived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008; 26: 1913-1919.
11. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432.
12. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16: 403-412.
13. Ringden O, Uzunel M, Sundberg B, Lönnies L, Nava S, Gustafsson J et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007; 21: 2271-2276. (Pubitemid 350011699)
14. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732-1740.
15. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614-633.
16. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22: 593-599. (Pubitemid 351386730)
17. Neschadim A, McCart JA, Keating A, Medin JA. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1407-1416. (Pubitemid 350091394)
18. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-525. (Pubitemid 40592895)